AKR1B1 and familial dilated cardiomyopathy: AT-001 is a novel and potent oral aldose reductase inhibitor targeting AKR1B1 that is in phase 3 clinical development for the treatment of DCM (https://synapse.zhihuiya.com/clinical-progress-detail/0a5aea2aa5058d22852a258dea9d44aa).